⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 15, 2024

Supplementary Figure 10 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer Phillip M. Brailey Minjung Song Phillip D. Bartlett Ines Figueiredo Bora Gürel Christina Guo Verena Brucklacher-Waldert H. Lorraine Thompson Jude Akinwale Samantha E. Boyle Christine Rossant Neil R. Birkett Julia Pizzey Mark Maginn James Legg Richard Williams Colette M. Johnston Philip Bland‐Ward Johann S. de Bono Andrew J. Pierce

View at Publisher

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 10: hPSMA expression on RP1 tumour cells is lost over time, even in tumours dosed with HSA only

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Archer et al. (2024) studied this question.

synapsesocial.com/papers/68e6f2aeb6db64358766d82e https://doi.org/10.1158/1078-0432.25603513

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 10 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors2024
2Supplementary Figure 5 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors2024
3Supplementary Figure 5 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors2024
4Supplementary Figure 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors2024
5Supplementary Figure 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors2024

More related papers

Supplementary Figure 8 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors2024
Supplementary Figure 8 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors2024
Supplementary Figure 4 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors2024